Comparison of Neoadjuvant Treatment for Pancreatic Cancer: Astragalus Combined With Gemcitabine Versus Gemcitabine Alone - A Single-Center, Randomized, Double-Blind Study

NCT06234072 Phase 2 NOT_YET_RECRUITING

This study compare the efficacy of Astragalus combined with Gemcitabine to Gemcitabine alone as neoadjuvant treatment for pancreatic cancer.

Details

Lead sponsor	Shenzhen University General Hospital
Phase	Phase 2
Status	NOT_YET_RECRUITING
Enrolment	120
Start date	2024-02
Completion	2027-01

Conditions

• Pancreatic Cancer

Interventions

• Astragalus + Gemcitabine
• Gemcitabine alone

Primary outcomes

• Objective response rate (ORR) — From first dose of study medication until approximately 3 years
  Objective response rate (ORR) measures the overall treatment response by assessing the percentage of patients with complete or partial tumor shrinkage after treatment.

Countries

China